216 related articles for article (PubMed ID: 11896285)
21. Cisapride disposition in neonates and infants: in vivo reflection of cytochrome P450 3A4 ontogeny.
Kearns GL; Robinson PK; Wilson JT; Wilson-Costello D; Knight GR; Ward RM; van den Anker JN;
Clin Pharmacol Ther; 2003 Oct; 74(4):312-25. PubMed ID: 14534518
[TBL] [Abstract][Full Text] [Related]
22. Onset of xenobiotic metabolism in children: toxicological implications.
Cresteil T
Food Addit Contam; 1998; 15 Suppl():45-51. PubMed ID: 9602911
[TBL] [Abstract][Full Text] [Related]
23. Pharmacokinetics and Safety of Macrocyclic Gadobutrol in Children Aged Younger Than 2 Years Including Term Newborns in Comparison to Older Populations.
Kunze C; Mentzel HJ; Krishnamurthy R; Fleck R; Stenzel M; Bhargava R; Burrowes D; Sutter G; Schultze-Mosgau M; Santiuste M; Hahn G
Invest Radiol; 2016 Jan; 51(1):50-7. PubMed ID: 26340504
[TBL] [Abstract][Full Text] [Related]
24. Linezolid pharmacokinetics in pediatric patients: an overview.
Jungbluth GL; Welshman IR; Hopkins NK
Pediatr Infect Dis J; 2003 Sep; 22(9 Suppl):S153-7. PubMed ID: 14520140
[TBL] [Abstract][Full Text] [Related]
25. Human variability for metabolic pathways with limited data (CYP2A6, CYP2C9, CYP2E1, ADH, esterases, glycine and sulphate conjugation).
Dorne JL; Walton K; Renwick AG
Food Chem Toxicol; 2004 Mar; 42(3):397-421. PubMed ID: 14871582
[TBL] [Abstract][Full Text] [Related]
26. Toxicokinetics in infants and children in relation to the ADI and TDI.
Renwick AG
Food Addit Contam; 1998; 15 Suppl():17-35. PubMed ID: 9602909
[TBL] [Abstract][Full Text] [Related]
27. Review and evaluation of the potential impact of age- and gender-specific pharmacokinetic differences on tissue dosimetry.
Clewell HJ; Teeguarden J; McDonald T; Sarangapani R; Lawrence G; Covington T; Gentry R; Shipp A
Crit Rev Toxicol; 2002 Sep; 32(5):329-89. PubMed ID: 12389868
[TBL] [Abstract][Full Text] [Related]
28. Pediatric Clinical Pharmacology of Voriconazole: Role of Pharmacokinetic/Pharmacodynamic Modeling in Pharmacotherapy.
Kadam RS; Van Den Anker JN
Clin Pharmacokinet; 2016 Sep; 55(9):1031-43. PubMed ID: 26979736
[TBL] [Abstract][Full Text] [Related]
29. Novel advances in cytochrome P450 research.
Singh D; Kashyap A; Pandey RV; Saini KS
Drug Discov Today; 2011 Sep; 16(17-18):793-9. PubMed ID: 21864709
[TBL] [Abstract][Full Text] [Related]
30. Children's susceptibility to chemicals: a review by developmental stage.
Makri A; Goveia M; Balbus J; Parkin R
J Toxicol Environ Health B Crit Rev; 2004; 7(6):417-35. PubMed ID: 15586877
[TBL] [Abstract][Full Text] [Related]
31. Prediction of in vivo hepatic clearance and half-life of drug candidates in human using chimeric mice with humanized liver.
Sanoh S; Horiguchi A; Sugihara K; Kotake Y; Tayama Y; Ohshita H; Tateno C; Horie T; Kitamura S; Ohta S
Drug Metab Dispos; 2012 Feb; 40(2):322-8. PubMed ID: 22048522
[TBL] [Abstract][Full Text] [Related]
32. Meta-analysis of hepatic cytochrome P450 ontogeny to underwrite the prediction of pediatric pharmacokinetics using physiologically based pharmacokinetic modeling.
Upreti VV; Wahlstrom JL
J Clin Pharmacol; 2016 Mar; 56(3):266-83. PubMed ID: 26139104
[TBL] [Abstract][Full Text] [Related]
33. Modeling interchild differences in pharmacokinetics on the basis of subject-specific data on physiology and hepatic CYP2E1 levels: a case study with toluene.
Nong A; McCarver DG; Hines RN; Krishnan K
Toxicol Appl Pharmacol; 2006 Jul; 214(1):78-87. PubMed ID: 16464483
[TBL] [Abstract][Full Text] [Related]
34. Clonidine disposition in children; a population analysis.
Potts AL; Larsson P; Eksborg S; Warman G; Lönnqvist PA; Anderson BJ
Paediatr Anaesth; 2007 Oct; 17(10):924-33. PubMed ID: 17767627
[TBL] [Abstract][Full Text] [Related]
35. Pharmacokinetic Considerations in Designing Pediatric Studies of Proteins, Antibodies, and Plasma-Derived Products.
Mahmood I
Am J Ther; 2016; 23(4):e1043-56. PubMed ID: 27386959
[TBL] [Abstract][Full Text] [Related]
36. Incorporating population variability and susceptible subpopulations into dosimetry for high-throughput toxicity testing.
Wetmore BA; Allen B; Clewell HJ; Parker T; Wambaugh JF; Almond LM; Sochaski MA; Thomas RS
Toxicol Sci; 2014 Nov; 142(1):210-24. PubMed ID: 25145659
[TBL] [Abstract][Full Text] [Related]
37. Physiologically based pharmacokinetic (PB-PK) models in the study of the disposition and biological effects of xenobiotics and drugs.
Andersen ME
Toxicol Lett; 1995 Dec; 82-83():341-8. PubMed ID: 8597075
[TBL] [Abstract][Full Text] [Related]
38. BAY 94-9027, a PEGylated recombinant factor VIII, exhibits a prolonged half-life and higher area under the curve in patients with severe haemophilia A: Comprehensive pharmacokinetic assessment from clinical studies.
Shah A; Coyle T; Lalezari S; Fischer K; Kohlstaedde B; Delesen H; Radke S; Michaels LA
Haemophilia; 2018 Sep; 24(5):733-740. PubMed ID: 29963724
[TBL] [Abstract][Full Text] [Related]
39. Rufinamide: clinical pharmacokinetics and concentration-response relationships in patients with epilepsy.
Perucca E; Cloyd J; Critchley D; Fuseau E
Epilepsia; 2008 Jul; 49(7):1123-41. PubMed ID: 18503564
[TBL] [Abstract][Full Text] [Related]
40. Population pharmacokinetics and pharmacokinetics/pharmacodynamics of bendamustine in pediatric patients with relapsed/refractory acute leukemia.
Darwish M; Megason G; Bond M; Hellriegel E; Robertson P; Grasela T; Phillips L
Curr Med Res Opin; 2014 Nov; 30(11):2305-15. PubMed ID: 25105914
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
